-10.9% lean body mass over 72 weeks) per the SURMOUNT-1 body-composition substudy [12]
Her writing has appeared in The Wall Street Journal , where she was a staff reporter, as well as in The New York Times , The New Yorker , Wired , Businessweek , and elsewhere
For context, semaglutide and tirzepatide do not produce dysesthesia at clinically significant rates, though a recent paper in PMC examined allodynia and dysesthesia reports across GLP-1 medications more broadly
Disturbances in GSH homeostasis are implicated in numerous human diseases, including cancer, pathologies associated to aging, cardiovascular, inflammatory, immune degenerative diseases (Ballaroti et al